Expression of CD40 Ligand on T Cells and Soluble CD40 Ligand in Children With Kawasaki Disease: A Single-Center Preliminary Study From North India.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Aug 2021
01 Aug 2021
Historique:
pubmed:
28
1
2020
medline:
19
8
2021
entrez:
28
1
2020
Statut:
ppublish
Résumé
This study was done to examine the role of CD40 ligand (CD40L) in children with Kawasaki disease (KD). There is paucity of literature on this aspect of KD. This was a case-control study of patients with KD diagnosed at the Allergy Immunology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India. CD40L expression on activated CD3+ T cells was measured using flow cytometry, and soluble CD40L (sCD40L) was measured using enzyme-linked immunosorbent assay. We included 14 children with KD, 14 healthy controls, and 12 febrile controls for the purpose of this study. Mean percentage CD40L expression was higher in patients with KD (before administration of intravenous immunoglobulin [IVIg]) as compared with normal and febrile controls. This difference was statistically significant when compared with normal control (p = 0.00; confidence interval [CI], 8.92-20.30), but was not statistically significant when compared with febrile controls (p = 0.138; CI, -3.50 to 22.08). CD40L expression decreased after giving IVIg, but the difference was not statistically significant (p = 0.073; CI, -1.04 to 19.73). Mean sCD40L values increased significantly after giving IVIg (when repeated after a median period of 11 days; p = 0.001; CI, -0.77 to -0.29). There was no statistically significant difference between mean sCD40L in patients with KD (before giving IVIg) as compared with normal and febrile controls (p = 0.42; CI, -1.11 to -0.51 and p = 0.641; CI, -0.37 to 0.57, respectively). CD40L may have important role in the pathogenesis of KD. However, these results need to be validated in larger multicenter studies.
Sections du résumé
BACKGROUND/OBJECTIVE
OBJECTIVE
This study was done to examine the role of CD40 ligand (CD40L) in children with Kawasaki disease (KD). There is paucity of literature on this aspect of KD.
METHODS
METHODS
This was a case-control study of patients with KD diagnosed at the Allergy Immunology Unit, Postgraduate Institute of Medical Education and Research, Chandigarh, India. CD40L expression on activated CD3+ T cells was measured using flow cytometry, and soluble CD40L (sCD40L) was measured using enzyme-linked immunosorbent assay.
RESULTS
RESULTS
We included 14 children with KD, 14 healthy controls, and 12 febrile controls for the purpose of this study. Mean percentage CD40L expression was higher in patients with KD (before administration of intravenous immunoglobulin [IVIg]) as compared with normal and febrile controls. This difference was statistically significant when compared with normal control (p = 0.00; confidence interval [CI], 8.92-20.30), but was not statistically significant when compared with febrile controls (p = 0.138; CI, -3.50 to 22.08). CD40L expression decreased after giving IVIg, but the difference was not statistically significant (p = 0.073; CI, -1.04 to 19.73). Mean sCD40L values increased significantly after giving IVIg (when repeated after a median period of 11 days; p = 0.001; CI, -0.77 to -0.29). There was no statistically significant difference between mean sCD40L in patients with KD (before giving IVIg) as compared with normal and febrile controls (p = 0.42; CI, -1.11 to -0.51 and p = 0.641; CI, -0.37 to 0.57, respectively).
CONCLUSIONS
CONCLUSIONS
CD40L may have important role in the pathogenesis of KD. However, these results need to be validated in larger multicenter studies.
Identifiants
pubmed: 31985724
pii: 00124743-202108000-00005
doi: 10.1097/RHU.0000000000001283
doi:
Substances chimiques
CD40 Ligand
147205-72-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
194-200Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. Circulation . 2017;135:e927–e999.
Wang CL, Wu YT, Liu CA, et al. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics . 2003;111:E140–E147.
Pi L, Che D, Long H, et al. Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease. Drug Des Devel Ther . 2018;12:1353–1362.
Chen KD, Huang YH, Ming-Huey Guo M, et al. The human blood DNA methylome identifies crucial role of β-catenin in the pathogenesis of Kawasaki disease. Oncotarget . 2018;9:28337–28350.
Singh S, Kawasaki T. Kawasaki disease in India, lessons learnt over the last 20 years. Indian Pediatr . 2016;53:119–124.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Circulation . 2004;110:2747–2771.
Onouchi Y, Ozaki K, Burns JC, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet . 2012;44:517–521.
Yahata T, Suzuki C, Yoshioka A, et al. Platelet activation dynamics evaluated using platelet-derived microparticles in Kawasaki disease. Circ J . 2014;78:188–193.
Kim HJ, Choi EH, Lim YJ, et al. The usefulness of platelet-derived microparticle as biomarker of antiplatelet therapy in Kawasaki disease. J Korean Med Sci . 2017;32:1147–1153.
Yan J, Wu ZG, Kong XT, et al. Relation between upregulation of CD40 system and complex stenosis morphology in patients with acute coronary syndrome. Acta Pharmacol Sin . 2004;25:251–256.
Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother . 2004;38:1500–1508.
Antoniades C, Bakogiannis C, Tousoulis D, et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol . 2009;54:669–677.
Pamukcu B, Lip GY, Snezhitskiy V, et al. The CD40-CD40L system in cardiovascular disease. Ann Med . 2011;43:331–340.
Ferroni P, Santilli F, Guadagni F, et al. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr Med Chem . 2007;14:2170–2180.
Abu el-Makrem MA, Mahmoud YZ, Sayed D, et al. The role of platelets CD40 ligand (CD154) in acute coronary syndromes. Thromb Res . 2009;124:683–688.
Liu DM, Yan JC, Wang CP, et al. The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta Int J Clin Chem . 2008;397:22–26.
Yan J, Chen G, Gong J, et al. Upregulation of OX40-OX40 ligand system on T lymphocytes in patients with acute coronary syndromes. J Cardiovasc Pharmacol . 2009;54:451–455.
Anand SX, Viles-Gonzalez JF, Badimon JJ, et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost . 2003;90:377–384.
Rizvi M, Pathak D, Freedman JE, et al. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med . 2008;14:530–538.
Pinto FF, Gomes I, Loureiro P, et al. Vascular function long term after Kawasaki disease: another piece of the puzzle? Cardiol Young . 2017;27:488–497.
Ghelani SJ, Singh S, Manojkumar R. Endothelial dysfunction in a cohort of north Indian children with Kawasaki disease without overt coronary artery involvement. J Cardiol . 2009;53:226–231.
Ikemoto Y, Ogino H, Teraguchi M, et al. Evaluation of preclinical atherosclerosis by flow-mediated dilatation of the brachial artery and carotid artery analysis in patients with a history of Kawasaki disease. Pediatr Cardiol . 2005;26:782–786.
Dhillon R, Clarkson P, Donald AE, et al. Endothelial dysfunction late after Kawasaki disease. Circulation . 1996;94:2103–2106.
Dietz SM, Tacke CEA, Hutten BA, et al. Peripheral endothelial (dys)function, arterial stiffness and carotid intima-media thickness in patients after Kawasaki disease: a systematic review and meta-analyses. PloS One . 2015;10:e0130913.
Noto N, Okada T, Karasawa K, et al. Age-related acceleration of endothelial dysfunction and subclinical atherosclerosis in subjects with coronary artery lesions after Kawasaki disease. Pediatr Cardiol . 2009;30:262–268.
Niboshi A, Hamaoka K, Sakata K, et al. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr . 2008;167:189–196.
Meena RS, Rohit M, Gupta A, et al. Carotid intima-media thickness in children with Kawasaki disease. Rheumatol Int . 2014;34:1117–1121.
Dietz SM, Tacke CE, Gort J, et al. Carotid intima-media thickness in patients with a history of Kawasaki disease. Circ J . 2015;79:2682–2687.
Gopalan K, Singh S, Vignesh P, et al. Carotid intima-media thickness and lipid profile in children with Kawasaki disease: a single-center follow-up study after a mean duration of 6.9 years. J Clin Rheumatol . 2018;24:385–389.
Schäfer M, Truong U, Ivy DD, et al. Children with Kawasaki disease present elevated stiffness of great arteries: phase-contrast MRI study. J Magn Reson Imaging . 2018;48:1228–1236.
Qureshi AM, Agrawal H. Catheter-based anatomic and functional assessment of coronary arteries in anomalous aortic origin of a coronary artery, myocardial bridges and Kawasaki disease. Congenit Heart Dis . 2017;12:615–618.
McCrindle BW, McIntyre S, Kim C, et al. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis? J Pediatr . 2007;151:244–248, 248.e1.
Takahashi K, Oharaseki T, Naoe S. Pathological study of postcoronary arteritis in adolescents and young adults: with reference to the relationship between sequelae of Kawasaki disease and atherosclerosis. Pediatr Cardiol . 2001;22:138–142.
Campbell AJ, Burns JC. Adjunctive therapies for Kawasaki disease. J Infect . 2016;72(Suppl):S1–S5.
Duan C, Du ZD, Wang Y, et al. Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease. World J Pediatr WJP . 2014;10:232–237.
Huang SM, Weng KP, Chang JS, et al. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J . 2008;72:1583–1587.
Hamaoka A, Hamaoka K, Yahata T, et al. Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease. J Cardiol . 2010;56:245–253.
Blankier S, McCrindle BW, Ito S, et al. The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clin Exp Immunol . 2011;164:193–201.
Santini E, Madec S, Corretti V, et al. Effect of statins on soluble CD40 ligand in hypercholesterolemic type 2 diabetic patients. J Endocrinol Invest . 2008;31:660–665.